nodes	percent_of_prediction	percent_of_DWPC	metapath
Icatibant—ANPEP—Metabolism of Angiotensinogen to Angiotensins—ACE—systemic scleroderma	0.0926	0.183	CbGpPWpGaD
Icatibant—BDKRB2—ACE Inhibitor Pathway—ACE—systemic scleroderma	0.0807	0.159	CbGpPWpGaD
Icatibant—BDKRB2—smooth muscle tissue—systemic scleroderma	0.0621	0.175	CbGeAlD
Icatibant—BDKRB2—tendon—systemic scleroderma	0.0467	0.132	CbGeAlD
Icatibant—ANPEP—connective tissue—systemic scleroderma	0.0423	0.12	CbGeAlD
Icatibant—BDKRB2—lung—systemic scleroderma	0.0409	0.116	CbGeAlD
Icatibant—ANPEP—smooth muscle tissue—systemic scleroderma	0.0387	0.109	CbGeAlD
Icatibant—ANPEP—skin of body—systemic scleroderma	0.0382	0.108	CbGeAlD
Icatibant—BDKRB2—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.0376	0.0742	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.0347	0.0685	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—GDF15—systemic scleroderma	0.0324	0.064	CbGpPWpGaD
Icatibant—ANPEP—digestive system—systemic scleroderma	0.0306	0.0863	CbGeAlD
Icatibant—ANPEP—tendon—systemic scleroderma	0.0291	0.0821	CbGeAlD
Icatibant—BDKRB2—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.0272	0.0537	CbGpPWpGaD
Icatibant—ANPEP—lung—systemic scleroderma	0.0255	0.0721	CbGeAlD
Icatibant—BDKRB2—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.0248	0.0491	CbGpPWpGaD
Icatibant—ANPEP—Peptide hormone metabolism—ACE—systemic scleroderma	0.0244	0.0481	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—IRF5—systemic scleroderma	0.02	0.0396	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.0194	0.0383	CbGpPWpGaD
Icatibant—ANPEP—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.0109	0.0216	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (q) signalling events—EDN1—systemic scleroderma	0.00905	0.0179	CbGpPWpGaD
Icatibant—BDKRB2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00894	0.0177	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.0081	0.016	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—MMP2—systemic scleroderma	0.00742	0.0147	CbGpPWpGaD
Icatibant—BDKRB2—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00611	0.0121	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.006	0.0118	CbGpPWpGaD
Icatibant—Injection site reaction—Mycophenolate mofetil—systemic scleroderma	0.00528	0.0378	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—RHOB—systemic scleroderma	0.00505	0.00998	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—ACE—systemic scleroderma	0.0046	0.00908	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—RHOB—systemic scleroderma	0.00459	0.00907	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—EDN1—systemic scleroderma	0.00457	0.00902	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.0041	0.0081	CbGpPWpGaD
Icatibant—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00403	0.0289	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—SMAD7—systemic scleroderma	0.0035	0.00692	CbGpPWpGaD
Icatibant—Anaphylactic shock—Mometasone—systemic scleroderma	0.00348	0.0249	CcSEcCtD
Icatibant—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00319	0.0228	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—CCL2—systemic scleroderma	0.00312	0.00617	CbGpPWpGaD
Icatibant—Anaphylactic shock—Captopril—systemic scleroderma	0.00306	0.0219	CcSEcCtD
Icatibant—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00297	0.0213	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—MMP1—systemic scleroderma	0.00295	0.00583	CbGpPWpGaD
Icatibant—Body temperature increased—Mometasone—systemic scleroderma	0.00275	0.0197	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—RHOB—systemic scleroderma	0.00271	0.00536	CbGpPWpGaD
Icatibant—Dizziness—Pentoxifylline—systemic scleroderma	0.00267	0.0191	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—EDN1—systemic scleroderma	0.00258	0.0051	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HSPG2—systemic scleroderma	0.00256	0.00505	CbGpPWpGaD
Icatibant—Rash—Pentoxifylline—systemic scleroderma	0.00254	0.0182	CcSEcCtD
Icatibant—Dermatitis—Pentoxifylline—systemic scleroderma	0.00254	0.0182	CcSEcCtD
Icatibant—Headache—Pentoxifylline—systemic scleroderma	0.00253	0.0181	CcSEcCtD
Icatibant—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00252	0.018	CcSEcCtD
Icatibant—Nervous system disorder—Leflunomide—systemic scleroderma	0.00247	0.0177	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—CSK—systemic scleroderma	0.00247	0.00488	CbGpPWpGaD
Icatibant—Body temperature increased—Captopril—systemic scleroderma	0.00242	0.0173	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—CCL2—systemic scleroderma	0.0024	0.00474	CbGpPWpGaD
Icatibant—Nausea—Pentoxifylline—systemic scleroderma	0.0024	0.0171	CcSEcCtD
Icatibant—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00236	0.0169	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—EDN1—systemic scleroderma	0.00234	0.00463	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—MMP2—systemic scleroderma	0.00228	0.00451	CbGpPWpGaD
Icatibant—Rash—Mometasone—systemic scleroderma	0.00219	0.0157	CcSEcCtD
Icatibant—Dermatitis—Mometasone—systemic scleroderma	0.00219	0.0157	CcSEcCtD
Icatibant—Headache—Mometasone—systemic scleroderma	0.00218	0.0156	CcSEcCtD
Icatibant—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00216	0.0155	CcSEcCtD
Icatibant—Body temperature increased—Azathioprine—systemic scleroderma	0.00211	0.0151	CcSEcCtD
Icatibant—Nausea—Mometasone—systemic scleroderma	0.00207	0.0148	CcSEcCtD
Icatibant—Dizziness—Captopril—systemic scleroderma	0.00202	0.0145	CcSEcCtD
Icatibant—Body temperature increased—Leflunomide—systemic scleroderma	0.00199	0.0143	CcSEcCtD
Icatibant—Hypersensitivity—Azathioprine—systemic scleroderma	0.00197	0.0141	CcSEcCtD
Icatibant—Rash—Captopril—systemic scleroderma	0.00193	0.0138	CcSEcCtD
Icatibant—Dermatitis—Captopril—systemic scleroderma	0.00193	0.0138	CcSEcCtD
Icatibant—Headache—Captopril—systemic scleroderma	0.00191	0.0137	CcSEcCtD
Icatibant—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.0019	0.0136	CcSEcCtD
Icatibant—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.0019	0.0136	CcSEcCtD
Icatibant—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00186	0.0133	CcSEcCtD
Icatibant—Hypersensitivity—Leflunomide—systemic scleroderma	0.00186	0.0133	CcSEcCtD
Icatibant—Nausea—Captopril—systemic scleroderma	0.00182	0.013	CcSEcCtD
Icatibant—Dizziness—Azathioprine—systemic scleroderma	0.00176	0.0126	CcSEcCtD
Icatibant—Body temperature increased—Lisinopril—systemic scleroderma	0.00171	0.0122	CcSEcCtD
Icatibant—Rash—Azathioprine—systemic scleroderma	0.00168	0.012	CcSEcCtD
Icatibant—Dermatitis—Azathioprine—systemic scleroderma	0.00168	0.012	CcSEcCtD
Icatibant—Headache—Azathioprine—systemic scleroderma	0.00167	0.012	CcSEcCtD
Icatibant—Dizziness—Leflunomide—systemic scleroderma	0.00167	0.0119	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CCL2—systemic scleroderma	0.0016	0.00316	CbGpPWpGaD
Icatibant—Hypersensitivity—Lisinopril—systemic scleroderma	0.00159	0.0114	CcSEcCtD
Icatibant—Dizziness—Mycophenolic acid—systemic scleroderma	0.00159	0.0114	CcSEcCtD
Icatibant—Rash—Leflunomide—systemic scleroderma	0.00159	0.0114	CcSEcCtD
Icatibant—Dermatitis—Leflunomide—systemic scleroderma	0.00159	0.0114	CcSEcCtD
Icatibant—Nausea—Azathioprine—systemic scleroderma	0.00158	0.0113	CcSEcCtD
Icatibant—Headache—Leflunomide—systemic scleroderma	0.00158	0.0113	CcSEcCtD
Icatibant—Rash—Mycophenolic acid—systemic scleroderma	0.00152	0.0108	CcSEcCtD
Icatibant—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00151	0.0108	CcSEcCtD
Icatibant—Headache—Mycophenolic acid—systemic scleroderma	0.00151	0.0108	CcSEcCtD
Icatibant—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0107	CcSEcCtD
Icatibant—Nausea—Leflunomide—systemic scleroderma	0.0015	0.0107	CcSEcCtD
Icatibant—Dizziness—Lisinopril—systemic scleroderma	0.00143	0.0102	CcSEcCtD
Icatibant—Nausea—Mycophenolic acid—systemic scleroderma	0.00143	0.0102	CcSEcCtD
Icatibant—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.0014	0.01	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—EDN1—systemic scleroderma	0.00138	0.00273	CbGpPWpGaD
Icatibant—Rash—Lisinopril—systemic scleroderma	0.00136	0.00977	CcSEcCtD
Icatibant—Dermatitis—Lisinopril—systemic scleroderma	0.00136	0.00976	CcSEcCtD
Icatibant—Headache—Lisinopril—systemic scleroderma	0.00136	0.00971	CcSEcCtD
Icatibant—Nausea—Lisinopril—systemic scleroderma	0.00129	0.0092	CcSEcCtD
Icatibant—Anaphylactic shock—Prednisone—systemic scleroderma	0.00129	0.0092	CcSEcCtD
Icatibant—Nervous system disorder—Prednisone—systemic scleroderma	0.00126	0.00903	CcSEcCtD
Icatibant—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00898	CcSEcCtD
Icatibant—Rash—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00856	CcSEcCtD
Icatibant—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00855	CcSEcCtD
Icatibant—Headache—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00851	CcSEcCtD
Icatibant—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00806	CcSEcCtD
Icatibant—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00107	0.00769	CcSEcCtD
Icatibant—Nervous system disorder—Methotrexate—systemic scleroderma	0.00105	0.00754	CcSEcCtD
Icatibant—Body temperature increased—Prednisone—systemic scleroderma	0.00102	0.00728	CcSEcCtD
Icatibant—Hypersensitivity—Prednisone—systemic scleroderma	0.000947	0.00678	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—CCL2—systemic scleroderma	0.000946	0.00187	CbGpPWpGaD
Icatibant—Dizziness—Prednisone—systemic scleroderma	0.00085	0.00609	CcSEcCtD
Icatibant—Body temperature increased—Methotrexate—systemic scleroderma	0.000849	0.00608	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—NOS3—systemic scleroderma	0.000843	0.00167	CbGpPWpGaD
Icatibant—Rash—Prednisone—systemic scleroderma	0.000811	0.0058	CcSEcCtD
Icatibant—Dermatitis—Prednisone—systemic scleroderma	0.00081	0.0058	CcSEcCtD
Icatibant—Headache—Prednisone—systemic scleroderma	0.000805	0.00577	CcSEcCtD
Icatibant—Hypersensitivity—Methotrexate—systemic scleroderma	0.000792	0.00567	CcSEcCtD
Icatibant—Nausea—Prednisone—systemic scleroderma	0.000764	0.00547	CcSEcCtD
Icatibant—Dizziness—Methotrexate—systemic scleroderma	0.000711	0.00509	CcSEcCtD
Icatibant—Rash—Methotrexate—systemic scleroderma	0.000677	0.00485	CcSEcCtD
Icatibant—Dermatitis—Methotrexate—systemic scleroderma	0.000677	0.00485	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—MMP9—systemic scleroderma	0.000677	0.00134	CbGpPWpGaD
Icatibant—Headache—Methotrexate—systemic scleroderma	0.000673	0.00482	CcSEcCtD
Icatibant—Nausea—Methotrexate—systemic scleroderma	0.000638	0.00457	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—TGFB1—systemic scleroderma	0.000558	0.0011	CbGpPWpGaD
